Loading...
XJPX7733
Market cap17bUSD
Dec 20, Last price  
2,375.50JPY
1D
2.13%
1Q
-9.59%
Jan 2017
135.20%
Name

Olympus Corp

Chart & Performance

D1W1MN
XJPX:7733 chart
P/E
11.20
P/S
2.90
EPS
212.04
Div Yield, %
0.74%
Shrs. gr., 5y
-2.30%
Rev. gr., 5y
3.35%
Revenues
936.21b
+6.16%
813,538,000,000978,127,000,0001,061,786,000,0001,128,875,000,000980,803,000,000883,086,000,000847,105,000,000848,548,000,000743,851,000,000713,286,000,000764,671,000,000804,578,000,000748,050,000,000786,497,000,000793,862,000,000797,411,000,000730,544,000,000868,867,000,000881,923,000,000936,210,000,000
Net income
242.57b
+69.12%
-11,827,000,00028,564,000,00047,799,000,00057,969,000,000-114,810,000,00047,763,000,0007,381,000,000-48,985,000,0008,020,000,00013,627,000,000-8,737,000,00062,594,000,00078,191,000,00057,064,000,0008,147,000,00051,670,000,00012,918,000,000115,742,000,000143,432,000,000242,566,000,000
CFO
42.37b
-56.99%
10,025,000,00049,034,000,000108,400,000,00089,006,000,00041,628,000,00076,245,000,00032,917,000,00030,889,000,00025,233,000,00072,388,000,00066,811,000,00048,621,000,00090,194,000,00095,146,000,00066,943,000,000133,544,000,000124,122,000,000169,729,000,00098,490,000,00042,365,000,000
Dividend
Mar 28, 20250 JPY/sh
Earnings
Feb 12, 2025

Profile

Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through four segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, endoscopy system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Others segment offers biomedical materials and orthopedic equipment. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.
URL
https://www.olympus.co.jp/
IPO date
May 16, 1949
Employees
32,844
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
936,210,000
6.16%
881,923,000
1.50%
868,867,000
18.93%
Cost of revenue
900,338,000
797,969,000
803,044,000
Unusual Expense (Income)
NOPBT
35,872,000
83,954,000
65,823,000
NOPBT Margin
3.83%
9.52%
7.58%
Operating Taxes
8,881,000
44,304,000
33,903,000
Tax Rate
24.76%
52.77%
51.51%
NOPAT
26,991,000
39,650,000
31,920,000
Net income
242,566,000
69.12%
143,432,000
23.92%
115,742,000
795.97%
Dividends
(20,057,000)
(17,822,000)
(15,428,000)
Dividend yield
0.75%
0.61%
0.51%
Proceeds from repurchase of equity
(180,002,000)
(71,210,000)
2,809,000
BB yield
6.69%
2.42%
-0.09%
Debt
Debt current
69,988,000
49,970,000
52,281,000
Long-term debt
276,411,000
332,851,000
376,610,000
Deferred revenue
84,996,000
107,384,000
Other long-term liabilities
103,718,000
18,194,000
16,069,000
Net debt
(84,923,000)
113,143,000
42,410,000
Cash flow
Cash from operating activities
42,365,000
98,490,000
169,729,000
CAPEX
(46,425,000)
(70,623,000)
(61,771,000)
Cash from investing activities
359,992,000
(58,414,000)
(71,016,000)
Cash from financing activities
(276,010,000)
(143,178,000)
(40,667,000)
FCF
3,142,000
(27,921,000)
21,517,000
Balance
Cash
340,933,000
180,689,000
312,841,000
Long term investments
90,389,000
88,989,000
73,640,000
Excess cash
384,511,500
225,581,850
343,037,650
Stockholders' equity
767,171,000
1,136,941,000
941,062,000
Invested Capital
776,008,500
759,332,150
643,551,350
ROIC
3.52%
5.65%
5.15%
ROCE
3.06%
8.42%
6.58%
EV
Common stock shares outstanding
1,216,241
1,268,371
1,283,603
Price
2,212.50
-4.57%
2,318.50
-0.88%
2,339.00
2.10%
Market cap
2,690,933,212
-8.49%
2,940,718,164
-2.05%
3,002,347,417
1.89%
EV
2,606,010,212
3,614,781,164
3,521,301,417
EBITDA
101,812,000
150,695,000
130,438,000
EV/EBITDA
25.60
23.99
27.00
Interest
10,306,000
8,175,000
5,381,000
Interest/NOPBT
28.73%
9.74%
8.17%